



Sense multiple targets at an enhanced RNA level.

Only the Aptima Combo 2 assay for *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) uses target capture of rRNA with proven detection for improved patient care.

Proven rRNA detection for better patient care

Chlamydia and gonorrhea are the most common notifiable sexually transmitted infections. Left untreated, they can cause infertility and other serious health complications.¹ Therefore, early detection is critically important.

***C trachomatis* and *N gonorrhoeae* infections can cause pelvic inflammatory disease (PID)¹**

Up to 30% of women with infections develop PID, and the majority have symptoms too mild or unspecific for them to seek medical care. PID can have serious health consequences for women:¹

- ▶ **20%** may become infertile.
- ▶ **18%** may experience debilitating chronic pelvic pain.
- ▶ **9%** may have a life-threatening tubal pregnancy.



Only the Aptima Combo 2 assay for CT/NG targets rRNA for proven detection—giving physicians trusted results and helping protect patients from the long-term consequences of PID.

The Aptima Combo 2 assay is uniquely designed to outperform DNA assays

- ▶ Provides an upfront biological advantage compared with assays that detect DNA—up to 1,000-fold more rRNA than DNA per cell.²
- ▶ Minimizes false negatives by removing potential amplification inhibitors.³
- ▶ Allows multiple sample types to be run simultaneously.

Excellent detection across specimen types

The Aptima Combo 2 assay demonstrated the same excellent sensitivity and specificity for CT and NG detection for each specimen type.³

Aptima Combo 2 Assay³

SPECIMEN TYPE	CT		NG	
	SENSITIVITY	SPECIFICITY	SENSITIVITY	SPECIFICITY
Clinician-collected Vaginal Swab/ Patient-collected Vaginal Swab	97.2%	98.5%	97.7%	99.6%
Endocervical Swab	97.2%	99.3%	100.0%	99.8%
Male Urethral Swab	100.0%	99.1%	100.0%	100.0%
ThinPrep® Solution	98.2%	100.0%	100.0%	100.0%

The Aptima Combo 2 assay demonstrates up to 100% detection of *N gonorrhoeae*.^{3,4}

Multiple sample types make the Aptima Combo 2 assay easy to order as a stand-alone test or in addition to the ThinPrep® Pap Test



References:

1. Centers for Disease Control and Prevention. *Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014*. Atlanta, GA: Centers for Disease Control and Prevention; 2014. *Morbidity and Mortality Weekly Report*; vol 63, no 2. <http://www.cdc.gov/mmwr/pdf/rr/rr6302.pdf>. Published March 14, 2014. Accessed February 24, 2015.
2. Chernesky M, Jang D, Luinstra K, et al. High analytical sensitivity and low rates of inhibition may contribute to detection of *Chlamydia trachomatis* in significantly more women by the APTIMA Combo 2 assay. *J Clin Microbiol*. 2006;44(2):400-405.
3. Aptima Combo 2 Assay (Panther system) [package insert]. San Diego, CA; Hologic, Inc., 2013.
4. Chernesky M, Jang D, Gilchrist J, et al. Head-to-head comparison of second-generation nucleic acid amplification tests for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* on urine samples from female subjects and self-collected vaginal swabs. *J Clin Microbiol*. 2014;52(7):2305-2310.

SS-00268-001 Rev. 001 © 2015 Hologic, Inc. All rights reserved. Hologic, The Science of Sure, Aptima, Aptima Combo 2, ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.

Aptima Combo 2®
Assay